ORPHAN MEDICAL REPORTS $5.4 MILLION REVENUE FOR FIRST QTR
2004.(Brief Article)
Orphan Medical, Inc. (Nasdaq:ORPH), Minneapolis, has announced
results for the first quarter ended March 31, 2004. Revenue for the
quarter was $5.4 million, which includes $1 million of . . .
$40-50 MILLION IN CUBICIN SALES PROJECTED FOR 2004.(Cubist
Pharmaceuticals Inc.)
Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) has provided updated
information on the launch of its flagship product, Cubicin (daptomycin
for injection). CUBICIN was launched in November 2003 in the . . .
NORTH AMERICAN SCIENTIFIC 1ST QTR NET SALES DECREASE 35%.
North American Scientific, Inc. (NASDAQ: NASI), Chatsworth, Calif.,
has announced financial results for its first quarter ended January 31,
2004.
For the first quarter ended January 31, 2004, the . . .
MEDICIS REPORTS 2ND QTR FISCAL 2004 NET REVENUES OF $70.6
MIL.
Medicis (NYSE:MRX), Scottsdale, Ariz., has announced second quarter
fiscal 2004 net revenues of $70.6 million with "if- converted"
net income of $16.0 million, or $0.25 per diluted share, absent a . . .
ARROW REPORTS 1ST QTR FISCAL '04 NET INCOME INCREASED
26.3%.(Arrow International Inc.)
Arrow International, Inc. (NASDAQ:ARRO), Reading, Pa., has reported
that net sales for the first quarter of fiscal 2004 increased to $103.1
million from $88.8 million in the first quarter of fiscal . . .
SEROLOGICALS FIRST QTR 2004 REVENUES UP 66%.
Serologicals Corporation, Atlanta, (NASDAQ:SERO) has announced
financial results for the first quarter 2004.
"The first quarter of 2004 was marked by several significant
accomplishments which . . .
HAEMACURE REPORTS $1.06 MILLION NET CONSOLIDATED LOSS.
For the first quarter ended January 31, 2004, Haemacure Corporation
(TSX:HAE), Montreal, recorded sales of $1.22 million, compared with
$5.34 million for the first quarter of fiscal 2003. This . . .
APPLIED BIOSYSTEMS REPORTS 2ND QTR FISCAL 2004 EPS OF 25
CENTS.(Revenue data)
Applied Biosystems Group (NYSE:ABI), Foster City, Calif., an
Applera Corporation business, has reported that earnings per share were
$0.25 for the second quarter of fiscal 2004, compared to $0.14 . . .
AMERISOURCEBERGEN EXPECTS 5% INCREASED FISCAL 2004 EPS.
AmerisourceBergen Corporation (NYSE:ABC), Valley Forge expects
fiscal 2004 diluted earnings per share excluding special items to be in
the range of $4.10 per share to $4.20 per share, an . . .
MEDCATH REPORTS 4TH QTR NET REVENUE INCREASED 30.7%.(Company
Profile)
MedCath Corporation (NASDAQ:MDTH), Charlotte, N.C. a national
provider of cardiovascular services, has announced its operating results
for its fourth quarter and fiscal year ended Sept. 30, 2003.
. . .
VERIDIEN PROJECTS FIRST QTR 2004 PROFIT.(Veridien Corp. )
Veridien Corporation (OTCBB:VRDE), St Petersburg, Fla., projects
positive quarterly EBITDA and profitability in the first quarter, 2004.
The company continues to work diligently to do the . . .
MEDIMMUNE PLANS TO ACHIEVE $2 BILLION IN REVENUES BY
2009.(financial plans)
MedImmune, Inc. (NASDAQ:MEDI), Gaithersburg, Md., expects to
achieve $2 billion in total revenues by 2009, driven by investments in
its pipeline and the continued growth of its currently . . .
AGILENT EXPECTS TO EXCEED GUIDANCE FOR 1ST QTR RESULTS.(Brief
Article)
Agilent Technologies Inc. (NYSE:A), Palo Alto. Calif. expects its
results for the first fiscal quarter, ending Jan. 31, 2004, to be above
the guidance provided in early December.
First quarter . . .
INVITROGEN EXPECTS 16% REVENUE INCREASE FOR 2004.
Invitrogen Corporation (Nasdaq:IVGN), Carlbad, Calif., anticipates
revenue for 2004 at $890 million, an increase of 16 percent over 2003.
Additionally, the company expects pro forma earnings per . . .
AGILENT RETURNS TO PROFITABILITY IN 4TH QTR 2003.(Agilent
Technologies Inc.)(Company Profile)
Agilent Technologies Inc. (NYSE: A), Palo Alto, Calif., has
reported orders of $1.73 billion and revenue of $1.68 billion for the
fiscal fourth quarter ended Oct. 31, 2003. During the quarter, . . .
BOSTON SCIENTIFIC FIRST QTR 2004 NET INCOME INCREASES
100%.
Boston Scientific Corporation (NYSE:BSX), Natick, Mass., has
announced financial results for its first quarter ended March 31, 2004,
as well as preliminary information related to U.S. sales of . . .
MEDMIRA REPORTS 2ND QTR NET LOSS OF $996 THOUSAND.
MedMira Inc., (TSX Venture: MIR), Halifax, Nova Scotia, has
announced its financial results for the three-month period ending
January 31, 2004.
Unit sales were up 2% over the previous quarter, . . .
MONSANTO'S SEEDS/TRAITS EXPECTED TO DRIVE MID-TERM
GROWTH.(Monsanto Co. Agricultural Group)
Significant growth in Monsanto's seeds and traits business is
expected to drive the company's mid-term growth, according to Hugh
Grant, chairman, president and chief executive officer. . . .
2003 BIOTECH'S 2ND BEST YEAR AND 2004 LOOKS BETTER.
"Rising like a phoenix from the ashes, the biotech industry
re-emerged in 2003 recovering from the massive devaluation that took
place during the last three years," said G. Steven Burrill, CEO . . .
BIOXEL PHARMA REPORTS NET LOSS OF $3.5 MILLION FOR 9
MONTHS.(Company Profile)
Bioxel Pharma Inc., Sainte-Foy, Quebec,(TSX Venture Exchange: BIP),
a leading manufacturer of naturally derived taxanes and targeted
oncology drugs, has released its results for the third quarter . . .
|
|